A phase 3 trial of the drug dichlorphenamide in hyperkalemic and hypokalemic periodic paralysis is open at several U.S. and European centers
A multicenter study of the drug dichlorphenamide in 140 adults with hyperkalemic or hypokalemic periodic paralysis is open at sites in California, Kansas, Massachusetts, Minnesota, Missouri, New York, Ohio and Texas, as well as in France (not yet recruiting), Italy and the United Kingdom.
The investigators will determine whether dichlorphenamide, when compared to a placebo, reduces the number of attacks of weakness or paralysis that people with periodic paralysis experience over the course of a nine-week period.
After the nine-week period, all participants will receive open-label dichlorphenamide for one year.
The principal investigators are based at the University of Rochester (N.Y.), one of the study sites, and the trial is being sponsored by the U.S. National Institutes of Health. Contact Patty Smith in Rochester, N.Y., at (585) 275-4339.
For details and contact information for each study site, see Hyper- and Hypokalemic Periodic Paralysis Study (HYP-HOP); or enter NCT00494507 into the search box at ClinicalTrials.gov.